Approved indications: Sogroya is an FDA-approved, once-weekly human growth hormone analog used for replacement of endogenous growth hormone in adults with growth hormone deficiency and for treatment of growth failure due to inadequate secretion of growth hormone in pediatric patients 2.5 years of age and older.

Off-label uses: Some clinicians may consider Sogroya for other pediatric short-stature conditions where daily growth hormone is standard (for example, certain syndromic or small-for-gestational-age growth disorders), but current data come mainly from small or ongoing trials, and these uses are not FDA-approved.

Efficacy expectations: In adults, improvements in body composition (less trunk fat, more lean mass), energy, and quality of life generally appear over several months, with efficacy comparable to daily somatropin when IGF-1 levels are titrated into the target range; in children, first-year height velocity with Sogroya is similar to daily growth hormone, supporting catch-up growth over years as long as treatment continues while growth plates are open; compared with daily products, Sogroya’s main advantage is once-weekly dosing, which can improve convenience and adherence without sacrificing effectiveness.

Typical dosing and route: Sogroya is given by subcutaneous injection once weekly, any time of day, into the thigh, abdomen, upper arm, or buttocks with rotation of injection sites.

• Adults with growth hormone deficiency: Usual starting dose is 1.5 mg once weekly (1 mg once weekly in adults 65 years and older), with increases of about 0.5–1.5 mg every 2–4 weeks based on symptoms and IGF-1 levels, up to a maximum of 8 mg once weekly.
• Pediatric patients ≥2.5 years with growth hormone deficiency: Recommended dose is 0.16 mg/kg once weekly based on actual body weight, adjusted over time for growth response, side effects, and IGF-1, not to exceed 8 mg once weekly.
• Special populations: Start at 1 mg once weekly in adults with moderate hepatic impairment and do not exceed 4 mg weekly; Sogroya is not recommended in adults or children with severe hepatic impairment or in children with moderate hepatic impairment; women taking oral estrogen typically start at 2 mg once weekly.

How to take it: Use the prefilled pen as instructed, inject under the skin (not into muscle or vein), with or without food, on the same day each week; visually check that the solution is clear to slightly opalescent and colorless to slightly yellow before use, and do not use cloudy or particulate solution.

Missed-dose guidance: If a dose is missed, it may be taken as soon as remembered within 3 days (72 hours) after the scheduled day, then resume the usual weekly schedule; if more than 3 days have passed, skip the missed dose and take the next dose on the regular scheduled day without doubling.

Overdose: Taking more than prescribed may cause symptoms of too much growth hormone (such as fluid retention, joint pain, or changes in blood sugar) and, with very large overdoses, acute blood sugar disturbances; immediate medical evaluation, including contacting emergency services or a poison control center, is recommended if an overdose is suspected.

Common side effects: Many people tolerate Sogroya well, but common effects (often mild to moderate and more frequent early in treatment or after dose increases) include back or joint pain, pain in arms or legs, indigestion or stomach upset, sleep problems, dizziness, cold-like symptoms, tonsillitis, fluid retention with swelling of hands or feet, headache, injection-site reactions, weight gain, mild increases in blood pressure, and blood-test changes such as higher creatine phosphokinase or mild anemia.

Serious or rare adverse effects:

• Severe allergic reactions (rash, hives, swelling of face or throat, trouble breathing).
• Increased pressure in the skull (severe headache, vision changes, nausea/vomiting) or papilledema on eye exam.
• Pancreatitis (severe, persistent abdominal pain, often with nausea or vomiting).
• Marked fluid retention, carpal tunnel symptoms, or heart strain.
• High blood sugar or new/worsening diabetes, or low adrenal or thyroid function.
• In children, hip or knee pain with limping (possible slipped capital femoral epiphysis) or progression of scoliosis.
• Increased risk of tumor growth or recurrence in people with current or past cancers, especially those previously irradiated to the brain/head.

Warnings and precautions: Sogroya must not be used in people with acute critical illness (after major surgery, trauma, or acute respiratory failure), active malignancy, active proliferative or severe nonproliferative diabetic retinopathy, closed growth plates when used to promote height, or in children with Prader–Willi syndrome who are severely obese or have serious breathing problems; caution and careful monitoring are needed in patients with diabetes, prior cancer or brain irradiation, intracranial hypertension, adrenal or thyroid insufficiency, or liver disease (not recommended in severe hepatic impairment and in children with moderate or severe hepatic impairment).

Pregnancy, breastfeeding, and age limits: Safety in pregnancy and breastfeeding is not well established, so use is generally avoided unless the potential benefit clearly outweighs the risk; Sogroya is approved only for children 2.5 years and older with open growth plates and for adults, and lower starting doses are used in older adults and those with certain organ impairments.

Overall safety profile: The types of side effects seen with Sogroya are generally similar to those of other recombinant growth hormone products, and long-acting weekly dosing has not revealed major new safety concerns, though long-term experience is more limited than with daily somatropin.

Reporting side effects and safety updates: Side effects should be reported to a healthcare professional and can also be reported directly to the FDA’s MedWatch program or to the manufacturer’s drug-safety line; updated safety information is available in the full prescribing information and on FDA and manufacturer websites.

Drug and substance interactions:

• Glucocorticoids: Oral or injectable steroids can blunt the growth-promoting effect of growth hormone; patients on replacement glucocorticoids may need dose adjustments when Sogroya is started.
• Oral estrogen: Estrogen taken by mouth lowers circulating IGF-1, so women on oral estrogen often require higher Sogroya doses and careful monitoring.
• Insulin and other diabetes medicines: Growth hormone can raise blood sugar, so insulin or other antihyperglycemic doses may need adjustment and glucose should be monitored closely in people with or at risk for diabetes.
• CYP450-metabolized drugs: Growth hormone may modestly affect liver enzyme activity, potentially changing blood levels of some medicines (for example, certain anticonvulsants, antidepressants, or immunosuppressants), so additional monitoring or dose changes may occasionally be needed.
• Other hormones and supplements: Thyroid hormone, sex steroids, and androgens can modify the growth response; no specific food interactions are known, and moderate alcohol has no direct interaction but may worsen underlying liver or metabolic issues.

Key precautions and when use may be unsafe: Sogroya should not be used in active malignancy, acute critical illness (after major surgery, trauma, or acute respiratory failure), active proliferative or severe nonproliferative diabetic retinopathy, in children with closed epiphyses, or in children with Prader–Willi syndrome who are severely obese or have serious breathing problems; extra caution and individualized risk–benefit assessment are required in people with prior cancer, uncontrolled diabetes, intracranial hypertension, significant liver disease, or severe obesity and sleep apnea.

Monitoring needs:

• Serum IGF-1 levels (typically drawn 3–4 days after the prior dose) to guide titration and avoid excessive exposure.
• Fasting glucose and/or A1c to detect new or worsening diabetes, and periodic lipid profiles in adults.
• Thyroid and adrenal function tests, since growth hormone can unmask or worsen hypothyroidism or adrenal insufficiency.
• Eye examinations before starting and periodically during treatment to screen for papilledema or diabetic retinopathy.
• In children, regular monitoring of height, weight, growth velocity, and bone age, as well as assessment for hip pain or scoliosis progression.

Q: What is Sogroya used for?
A: Sogroya is a once-weekly injectable human growth hormone analog used to replace missing growth hormone in adults with growth hormone deficiency and to treat growth failure in children 2.5 years and older who do not make enough of their own growth hormone.

Q: How is Sogroya different from daily growth hormone shots?
A: Unlike traditional somatropin products that are injected every day, Sogroya is designed to last longer in the body so it only needs to be injected once a week, while providing similar effects on growth and body composition when doses are adjusted to the same IGF-1 range.

Q: How long does it take to notice results with Sogroya?
A: Many adults notice gradual changes in energy and body composition over several months, and children usually show increased height velocity within the first 6–12 months, with continued catch-up growth over several years if treatment is maintained and growth plates remain open.

Q: Where and how do I inject Sogroya?
A: Sogroya is injected under the skin of the thigh, abdomen, upper arm, or buttocks using a prefilled pen once a week, and injection sites should be rotated each week to reduce the risk of skin reactions or fat loss at the injection area.

Q: What should I do if I miss a Sogroya dose?
A: If you remember within 3 days of your scheduled injection, take the missed dose as soon as possible and then continue on your usual weekly schedule; if more than 3 days have passed, skip the missed dose and wait until your next regular injection day.

Q: Can Sogroya be used during pregnancy or while breastfeeding?
A: There is limited information about Sogroya in pregnancy and breastfeeding, so it is generally avoided unless clearly needed and any decision to continue or start treatment should be made with a clinician who can weigh the benefits and potential risks for both parent and child.

Storage: Keep Sogroya pens in the refrigerator at 36–46°F (2–8°C) with the cap on and in the original carton; unopened or in-use pens may be kept at room temperature up to 77°F (25°C) for a total of 72 hours, but must be discarded if they have been frozen, kept above 86°F (30°C), or if it has been more than 6 weeks since first use.

Handling: Protect the pen from direct heat and light, do not use it if the solution looks cloudy, colored, or contains particles, and always keep medicines out of the reach of children and pets.

Disposal: Place used needles immediately into an FDA-cleared sharps container, and dispose of used or expired pens and full sharps containers according to local or pharmacy guidance rather than in household trash.